MAGNOLIA, Texas, Feb. 4, 2026 /PRNewswire/ — Stratus® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.
The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis™basivertebral nerve ablation (BVNA) technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS® RF Multitined Expandable Electrode (Nimbus) design.
Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain.
The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.
Luke Larsen, Vice President at Wasatch Health Partners, said, “We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.”
Bret Boudousquie, CEO of Stratus Medical, commented, “We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.”
Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, “I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement. This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.”
Acerca de Stratus Medical
Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal. Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.
About Wasatch Health Partners
Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah.
Contacto para la prensa
Cody Jorgensen
Comunicaciones de marketing
Stratus Medical
346-703-0642
cody@stratusmedical.com
https://stratusmedical.com
English English 
Italiano
Português do Brasil
Português
Español
العربية
Antecedentes:
La neurotomía por radiofrecuencia (RFN) puede ser un tratamiento eficaz para pacientes con dolor de cuello crónico y cefaleas cervicogénicas resistentes a los cuidados conservadores. Sin embargo, el grado y la duración del alivio del dolor tras la RFN dependen de la exhaustividad de la coagulación del nervio diana.
Informe de un caso:
Éste es el caso de un paciente de 37 años con dolor cervical debilitante y cefaleas tras un accidente de tráfico. Un bloqueo anestésico local satisfactorio del tercer nervio occipital (TON) confirmó que el dolor tenía su origen en la articulación facetaria C2-C3. Un tratamiento inicial de RFN del TON, utilizando electrodos estándar 18G en modo bipolar, produjo una mejoría completa de los síntomas durante 8 meses. La repetición de la RFN, utilizando la misma configuración de electrodos, no consiguió aliviar el intenso dolor de cuello y las cefaleas, y no produjo ninguna pérdida sensorial demostrable en la distribución del TON. A continuación se realizó la RFN utilizando el electrodo expandible multidireccional de RF electroquirúrgico NIMBUS®, que proporciona una zona de coagulación de mayor volumen que los electrodos de RFN estándar, incluso cuando se utiliza en configuración bipolar.
Conclusión:
El procedimiento NIMBUS dio lugar a una coagulación satisfactoria del TON con pérdida sensorial en la distribución del TON y restablecimiento del alivio paliativo.
